Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PD-1 EXPRESSION INHIBITOR, PHARMACEUTICAL COMPOSITION FOR IMMUNE CHECKPOINT INHIBITION, AND METHOD FOR INHIBITING PD-1 EXPRESSION
Document Type and Number:
WIPO Patent Application WO/2023/053315
Kind Code:
A1
Abstract:
This PD-1 expression inhibitor contains at least one component selected from the group consisting of the following (a) through (d): (a) interleukin 36 or a modified form thereof; (b) a polynucleotide having a nucleotide sequence encoding either interleukin 36 or a modified form thereof; (c) a vector containing the polynucleotide described in the abovementioned (b); and (d) cells that secrete either interleukin 36 or a modified form thereof.

Inventors:
NUMASAKI MUNEO (JP)
Application Number:
PCT/JP2021/036056
Publication Date:
April 06, 2023
Filing Date:
September 30, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV TOHOKU (JP)
International Classes:
A61K38/20; A61K48/00; A61P35/00; A61P43/00
Foreign References:
JP2021070683A2021-05-06
CN110075275A2019-08-02
CN108524918A2018-09-14
Other References:
WEINSTEIN ALIYAH M., CHEN LU, BRZANA EMILY A., PATIL PRASHANTI R., TAYLOR JENNIFER L., FABIAN KELLSYE L., WALLACE CALLEN T., JONES: "Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment", ONCOIMMUNOLOGY, vol. 6, no. 6, 3 June 2017 (2017-06-03), XP093054638, DOI: 10.1080/2162402X.2017.1322238
WEINSTEIN ALIYAH M.; GIRALDO NICOLAS A.; PETITPREZ FLORENT; JULIE CATHERINE; LACROIX LAETITIA; PESCHAUD FRéDéRIQUE; EMIL: "Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 68, no. 1, 12 October 2018 (2018-10-12), Berlin/Heidelberg , pages 109 - 120, XP036671532, ISSN: 0340-7004, DOI: 10.1007/s00262-018-2259-0
QUEEN DAWN, EDIRIWEERA CHATHUMADAVI, LIU LIANG: "Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 7, XP093054646, DOI: 10.3389/fcell.2019.00317
WANG XUEFENG; ZHAO XIN; FENG CHAO; WEINSTEIN ALIYAH; XIA RUI; WEN WEN; LV QUANSHENG; ZUO SHUTING; TANG PEIJUN; YANG XI; CHEN XIAOJ: "IL-36y Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Respo", CANCER CELL, vol. 28, no. 3, 27 August 2015 (2015-08-27), US , pages 296 - 306, XP029268946, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2015.07.014
ZHAO XIN, CHEN XIAOJUAN, SHEN XINGHUA, TANG PEIJUN, CHEN CHEN, ZHU QITAI, LI MUYAO, XIA RUI, YANG XI, FENG CHAO, ZHU XINGUO, ZHU Y: "IL-36β Promotes CD8+ T Cell Activation and Antitumor Immune Responses by Activating mTORC1", FRONTIERS IN IMMUNOLOGY, vol. 10, 1 January 2019 (2019-01-01), XP093054648, DOI: 10.3389/fimmu.2019.01803
DING GUOPING, SHEN TAO, YAN CHEN, ZHANG MINGJIE, WU ZHENGRONG, CAO LIPING: "IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer", BMC CANCER, vol. 19, no. 1, 1 December 2019 (2019-12-01), XP093054651, DOI: 10.1186/s12885-019-6145-8
Attorney, Agent or Firm:
TANAI Sumio et al. (JP)
Download PDF: